International Clinical Trial: A Prospective, Single-Arm, Multicenter Clinical Study of Chidamide, Decitabine, PD-1 Monoclonal Antibody Combined with Pegaspargase (Epi-Immuno-Pe) in Elderly/Chemotherapy-Intolerant Patients with Relapsed or Refractory NK/T-Cell Lymphoma

Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117389) titled 'A Prospective, Single-Arm, Multicenter Clinical Study of Chidamide, Decitabine, PD-1 Monoclonal Antibody Combined with Pegaspargase (Epi-Immuno-Pe) in Elderly/Chemotherapy-Intolerant Patients with Relapsed or Refractory NK/T-Cell Lymphoma' on Jan. 23.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital, Zhejiang University School of Medicine

Condition: NK/T-Cell Lymphoma

Intervention: Epi-Immuno-Pe treatment group:Chidamide: 5 mg/tablet, oral, once daily, days 1-14 Decitabine: 20 mg/m^2 intravenous infusion, days 1-5 PD-1 inhibitor: 100 mg intravenous inf...